A Soft Robot Now Places the Tube Without a Glottic View. In the Study That Proved It, Every Placement Was Adjudicated by a Bronchoscope Passed Down the Tube.

Onboard Placement Confirmation for Operator-Independent Emergency Intubation

1. Problem Statement

Emergency airway management is one of the few procedures where the buyer of the technology and the payer for the failure are the same organisation, and the failure is counted in deaths rather than returns.

Prehospital first-pass intubation failure is "nearly 35%" (Haggerty et al., Science Translational Medicine, 2025), against a pooled prehospital first-pass success range of 59% to 98% (Hayes-Bradley et al., British Journal of Anaesthesia, 2024).

That spread of 39 percentage points is the commercial signal, and the ceiling above it is known: 85.1% first-attempt success with video laryngoscopy in 1,417 critically ill adults across 17 emergency departments and intensive care units (Prekker et al., New England Journal of Medicine, 2023; full result in section 3). That same trial found safety outcomes, including oesophageal intubation, similar between the video and direct arms, which is the strongest single piece of evidence that better viewing does not by itself fix confirmation. Best-in-class equipment with supervised physicians reaches 85%. The distance from there to a 59% prehospital floor is operator skill, which money cannot buy quickly.

The second failure mode is separable, and it is the expensive one. Within a Dutch series of 3,632 prehospital intubations, unrecognised oesophageal intubation before HEMS arrival ran at 37.5% with video laryngoscopy against 30.6% with direct laryngoscopy in the traumatic circulatory arrest subgroup, and at 0% against 20% in the medical cardiac arrest subgroup (Maissan et al., European Journal of Trauma and Emergency Surgery, 2022). Three qualifiers travel with those figures. They are subgroup rates, not cohort rates, and the abstract does not give their numerators and denominators. The direction reverses between the subgroups. And the paper's own conclusion attributes the traumatic-arrest reversal specifically to tubes placed by ambulance nurses before HEMS arrival, which is the least experienced operator class, and also the class an operator-independent device targets. What survives those qualifiers is the narrow point this brief rests on: upgrading the guidance instrument did not reliably resolve confirmation.

Who pays today. Clinician work bills under CPT 31500, "Intubation, endotracheal, emergency procedure," which per CPT and NCCI guidance covers emergency and not elective intubation, while prehospital work is bundled into advanced life support emergency ground transport (HCPCS A0427 and A0433 families), making a prehospital device a cost of service. The cost of the status quo lands on agencies as training spend and on health systems as the downstream cost of hypoxic injury, neither of which appears on a device invoice.

2. State of the Art

The incumbent category is the video laryngoscope, which requires the operator to obtain and interpret a glottic view. DEVICE quantified what that buys and what it does not: severe complications were 21.4% in the video group against 20.9% in the direct group. Better viewing improved placement and left the complication profile unchanged.

Robotic approaches stalled at teleoperation. The only in-human robotic tracheal intubation series is fourteen years old and joystick-driven (Hemmerling et al., British Journal of Anaesthesia, 2012; detail in section 3), and nothing has replaced it in humans. Spiro Robotics has clinically studied a joystick-driven robotic flexible intubation scope and states it is not cleared for commercial use.

September 2025 changed the category, through mechanics rather than computation. A group at UC Santa Barbara with co-investigators at UT Health San Antonio, Stanford and UPMC built a non-electronic tip-everting soft robot that guides a breathing tube into the trachea by growing along the airway, substituting morphology for perception. Eight EMS providers given roughly five minutes of training reached 86.9% first-pass success on cadavers with it, against 62.5% with a video laryngoscope (Haggerty et al., 2025; trial detail in section 3). That all-airways difference did not reach significance (P = 0.055), but in the difficult-airway subgroup it did: 92.9% against 35.7%, odds ratio 23.4 (95% CI 2.23 to 236), P = 0.002.

The limitation is structural. The device contains no electronics and no sensors. In the provider study, success was "verified by passing the Ambu aScope bronchoscope through the core of the ETT to provide a confirming view of tracheal rings." The proof that the tube went to the right place came from an instrument the device does not carry, operated by investigators who were not the user. A product that lets a five-minutes-trained responder place a tube hands that same responder the remaining hard judgment, is it in the trachea, with no new help. Waveform capnography remains the confirmation standard, and interpreting it under load is what the target user population is least equipped to do.

3. Foundational Research

Haggerty DA, Cazzoli JR, Wayne MA, Winckler CJ, Wampler DA, Jarvis JL, et al., Hawkes EW (2025). "A soft robotic device for rapid and self-guided intubation." Science Translational Medicine 17(815):eads7681. DOI 10.1126/scitranslmed.ads7681. PMID 40929248. A tip-everting soft overtube, 12 mm in diameter from 0.005 inch TPU film with a polycarbonate insert overmolded in lubricious silicone, everts along the airway and carries a soft endotracheal tube to the trachea without a glottic view. Testing ran in two stages: one expert user across 50 sequential mannequin intubations and 10 tests in a single fresh-frozen cadaver bust (cephala and torso, dissected at the shoulders and nipple line), then eight EMS providers using the device and a video laryngoscope on eight unembalmed adult cadavers after a 3-minute device video, a 5-minute video-laryngoscopy video and one practice attempt with each. Expert results were 100% success at mean duration under 8 seconds. In the provider study (Table 2, all users, all airways), first-pass success was 86.9% for the device against 62.5% for video laryngoscopy (odds ratio 4.0, 95% CI 0.92 to 17, P = 0.055, not significant); overall success 95.7% against 91.7% (P = 0.576); mean attempts 1.1 against 1.6 (P = 0.062); and overall duration 20.8 seconds against 44.4 seconds (P = 0.008), the only significant whole-cohort result. In the difficult-airway subgroup, 14 trials per arm, first-pass success was 92.9% against 35.7% (odds ratio 23.4, 95% CI 2.23 to 236, P = 0.002), overall duration 23.7 against 64.4 seconds (P = 0.012), attempts 1.1 against 1.8 (P = 0.008). The authors call the study preliminary and state that no power analysis was used in sample size determination. Read precisely: operator-independent placement is achievable, its measured advantage is in difficult airways and in time rather than in all-airways first-pass, and the boundary of the claim is sharp. Cadavers have no muscle tone, laryngospasm, secretions or desaturation clock, and success was adjudicated by an investigator passing a bronchoscope through the tube.

Prekker ME, Driver BE, Trent SA, et al.; DEVICE Investigators (2023). "Video versus Direct Laryngoscopy for Tracheal Intubation of Critically Ill Adults." New England Journal of Medicine 389(5):418-429. DOI 10.1056/NEJMoa2301601. PMID 37326325. A multicenter randomised trial at 17 emergency departments and intensive care units assigned critically ill adults to video or direct laryngoscopy, primary outcome first-attempt success. Among 1,417 patients, first-attempt success was 85.1% (600 of 705) versus 70.8% (504 of 712), an absolute risk difference of 14.3 percentage points (95% CI 9.9 to 18.7, P < 0.001); the trial stopped early for efficacy. Severe complications were 21.4% versus 20.9% (absolute risk difference 0.5 percentage points, 95% CI −3.9 to 4.9). Funded by the U.S. Department of Defense (NCT05239195). This sets the benchmark any new device must clear and separates the value propositions: viewing improves placement and does not by itself improve the complication profile.

Maissan I, van Lieshout E, de Jong T, van Vledder M, Houmes RJ, den Hartog D, Stolker RJ (2022). "The impact of video laryngoscopy on the first-pass success rate of prehospital endotracheal intubation in The Netherlands: a retrospective observational study." European Journal of Trauma and Emergency Surgery 48(5):4205-4213. DOI 10.1007/s00068-022-01962-7. PMID 35362731. A retrospective analysis of 3,632 prehospital intubations by ambulance nurses, HEMS nurses and HEMS physicians using direct or video laryngoscopy. First-pass success stratified sharply by operator: ambulance nurses 45.5% (391 of 859) with direct and 64.8% (125 of 193) with video; HEMS nurses 57.6% (34 of 59) and 77.2% (125 of 162); HEMS physicians 85.9% (790 of 920) and 86.9% (1,251 of 1,439). The instrument mattered enormously for the least experienced and not at all for the most experienced, which is the quantitative case for operator-independent devices. The second finding defines this opportunity: unrecognised oesophageal intubation before HEMS arrival was 30.6% with direct and 37.5% with video laryngoscopy in the traumatic circulatory arrest subgroup, and 20% versus 0% in the medical cardiac arrest subgroup. These are subgroup rates, not rates over the 3,632-intubation series, and the abstract does not publish the numerator and denominator for each cell; the 20% and 0% figures in particular imply small counts. The direction also reverses between subgroups, so this is not a general claim that video laryngoscopy worsens confirmation. It is evidence that guidance and confirmation are separate problems and that solving the first does not reliably solve the second.

Hayes-Bradley C, McCreery M, Delorenzo A, Bendall J, Lewis A, Bowles KA (2024). "Predictive and protective factors for failing first pass intubation in prehospital rapid sequence intubation: an aetiology and risk systematic review with meta-analysis." British Journal of Anaesthesia 132(5):918-935. DOI 10.1016/j.bja.2024.02.004. PMID 38508943. A PRISMA systematic review with meta-analysis searching MEDLINE, EMBASE, CINAHL and the Cochrane Library to 3 March 2023 (PROSPERO CRD42022353609), covering first-pass success in prehospital rapid sequence intubation on live patients. First-pass success ranged 59% to 98%. Failure was predicted by age under one year, blood or fluid in the airway, restricted jaw or neck movement, trauma, nighttime procedures, distorted upper-airway anatomy and equipment issues; protective factors were an experienced intubator, training, certain video laryngoscopes, inclined stretcher positioning, a bougie and laryngeal manoeuvres. The authors note heterogeneity limits stronger conclusions. This defines the market segmentation: failure concentrates in identifiable subgroups, none of which appeared in the cadaver study above.

Li J (2001). "Capnography alone is imperfect for endotracheal tube placement confirmation during emergency intubation." Journal of Emergency Medicine 20(3):223-229. DOI 10.1016/s0736-4679(00)00318-8. PMID 11267809. A meta-analysis of experimental capnography trials in emergency populations, paired with an analysis of consecutive intubations reported to the National Emergency Airway Registry. Across 2,192 intubations, capnography showed aggregate sensitivity 93% (95% CI 92 to 94%) and specificity 97% (95% CI 93 to 99%) for emergency tube placement confirmation, giving a 7% false-negative rate (tube in trachea, capnography reports oesophagus) and a 3% false-positive rate (tube in oesophagus, capnography reports trachea), with a number needed to harm of 14, 33 and 10 respectively. Of 4,602 consecutive NEAR intubations, 4% resulted in accidental oesophageal intubation and 10% occurred in nontraumatic cardiac arrest patients. Two scope qualifiers travel with this paper. Its capnography accuracy figures treat tracheal placement as the positive class, the opposite convention to the one used for the proposed module below. And its observation that capnography was not recommended in cardiac arrest reflects 2001 practice: current American Heart Association guidance recommends continuous waveform capnography to confirm and monitor tube placement, including during CPR. What survives is physiological rather than procedural. In low-flow states exhaled carbon dioxide can be low or absent, so the modality that guidance now mandates is least informative exactly where the event rate is highest. The paper is 25 years old and the modern adjunct has similar limits: tracheal rapid ultrasound, against capnography as criterion standard, gave 98.2% accuracy (95% CI 93.7 to 99.5) in 112 emergency intubations of which 17 (15.2%) were oesophageal, at a median 9.0 seconds, but needs a trained sonographer (Chou HC, Tseng WP, Wang CH, Ma MH, Wang HP, Huang PC, et al. (2011). "Tracheal rapid ultrasound exam (T.R.U.E.) for confirming endotracheal tube placement during emergency intubation." Resuscitation 82(10):1279-1284. DOI 10.1016/j.resuscitation.2011.05.016. PMID 21684668; kappa 0.93, sensitivity 98.9%, specificity 94.1%, capnography as criterion standard).

Hemmerling TM, Taddei R, Wehbe M, Zaouter C, Cyr S, Morse J (2012). "First robotic tracheal intubations in humans using the Kepler intubation system." British Journal of Anaesthesia 108(6):1011-1016. DOI 10.1093/bja/aes034. PMID 22457483. A pilot study in 12 consented surgical patients of a joystick-teleoperated Kinova JACO arm driving a Pentax AWS video laryngoscope. Intubation succeeded in 11 of 12 (91%) at median total time 93 seconds (IQR 87 to 109, range 76 to 153); the failure was caused by laryngoscope fogging. This remains the only in-human robotic intubation dataset, it is teleoperated rather than autonomous, and it is fourteen years old, which measures how much of the category's stall belongs to sensing and control rather than mechanics.

4. Competitive Landscape

In the exact space, a device that places an endotracheal tube without requiring operator skill or a glottic view, one company was identified. The search covered company websites, the FDA 510(k) and classification databases, NIH RePORTER and the published literature; it did not cover SBIR.gov, DoD CDMRP or USAMRDC award records, BARDA, or private-market databases, so this is a bounded count rather than a certainty.

Vine Medical, Inc. (Santa Barbara, California) is the UCSB spinout founded by the first author of the 2025 paper, holding US Patent 12,280,208, "Vine Robot Tracheal Intubation Device." Two authors are employed by Vine Medical with an ownership stake and four more hold an ownership stake, per the paper's competing-interests statement; the work was supported in part by the National Science Foundation. UCSB states the company is preparing for clinical trials and FDA review, and no FDA clearance exists. No private funding round could be verified, but the paper's funding statement shows the work is federally supported and the resource asymmetry should not be understated: National Science Foundation award 1944816, National Science Foundation SBIR award 2305627, a David and Lucile Packard Foundation award (2020-71-383), and U.S. Army Medical Research Acquisition Activity award HT9425-23-1-0872. The competitor already holds both an NSF SBIR and an Army medical research award.

Three companies are adjacent, each attacking one failure factor rather than operator dependence.

IVOS Medical, Inc.: BOSS video laryngoscope sleeve with integrated continuous suction, aimed at the bloody-airway predictor. $2,143,514 in NIH NHLBI SBIR funding across FY2022 to FY2026 (itemised in section 7). Not autonomous; no FDA clearance located.
SmartAirway LLC: articulating stylet, one NIH NHLBI SBIR Phase I award ($313,365, FY2025). Preclinical.
Spiro Robotics: Spiro-VISTA teleoperated robotic flexible intubation scope, not cleared for commercial use.

Nobody is in the confirmation half. Waveform capnography is the standard and is sold as a monitoring accessory under FDA product code CCK (carbon-dioxide gaseous-phase gas analyzer, Class II, 21 CFR 868.1400). No product integrates automated placement adjudication into an airway device.

Why the space is not commoditised. The enabling mechanism is one year old at provider-study maturity, and the regulatory path for the guidance device is easy while the path for a confirmation claim is not, which inverts the usual incentive: a company can clear the mechanical device quickly and has every reason to ship before solving the harder problem. If Vine Medical clears and a first-in-human study reads out, expect competitive entry within 24 to 36 months, because the mechanism is published and the manufacturing is polymer extrusion and overmolding rather than precision electronics. The confirmation layer is the durable position.

5. Total Addressable Market

The market is defined narrowly: single-use, operator-independent endotracheal placement devices with onboard placement confirmation, sold into United States emergency medical services and emergency departments.

Bottom-up. The prehospital volume floor comes from the National EMS Information System: 76,123 patients intubated out of hospital in 2021, 68,027 in 2020 and 83,022 in 2019 (Huebinger et al., Annals of Emergency Medicine, 2023;82(6):763-765). Two limits travel with this number. NEMSIS is a voluntary registry that does not include every EMS agency, so the counts are a floor rather than a census; and the research letter's full text is paywalled, so the per-year counts here are as reported for that letter rather than read from its own tables.

Units consumed exceed patients intubated, because failed attempts consume units. The right multiplier is the device's own measured attempt ratio of 1.1 per success, not video laryngoscopy's 1.6, because units of this product are consumed at this product's rate; that gives roughly 84,000 single-use units per year on the registry floor. (The 1.1 against 1.6 difference is itself P = 0.062 and the study capped attempts at three, so treat 1.1 as a measured point estimate rather than a settled consumption rate.) Unit price is a stated assumption, not a sourced figure: single-use airway adjuncts and disposable video-laryngoscope blades sell in the tens to low hundreds of dollars, so the band used is $150 to $400.

This is a 100%-share ceiling, not a forecast: it assumes every prehospital intubation in the registry uses one of these devices and that no competing product takes share.

Units per year	At $150	At $250	At $400
84,000 (device attempt ratio 1.1)	$12.6M	$21.0M	$33.6M

This is below $100 million and the brief flags it. At $12.6 million to $33.6 million a year, a prehospital-only disposable business is not venture-scale at registry-floor volumes, across the whole price band. That is the most important number here, because it explains the structure of the opportunity rather than undermining it: the guidance device cannot carry a company on prehospital volume alone, which is why the confirmation layer, which also sells into every emergency department against an existing capnography budget, is where the value sits.

SAM. At TRL 4 to 5 with no living-airway data, the realistic first served segment is ALS-capable ground EMS agencies in structured evaluation plus emergency departments benchmarking against DEVICE. At the $250 midpoint against the 84,000-unit floor, near-term serviceable market is about $21 million per year, expanding with in-hospital emergency intubation volume, which this analysis does not separately source and therefore does not claim.

Top-down cross-check (publisher summary figures; the report page returns 403 to direct retrieval). Grand View Research, Airway Management Devices Market Size, Share and Trends Analysis Report, 2026-2033, puts the global airway management devices market at USD 2.64 billion in 2025, reaching USD 4.26 billion by 2033 at a 6.10% CAGR over 2026 to 2033, with North America at 38.54% revenue share in 2025 and infraglottic devices the largest segment at 33.0%. North American infraglottic devices therefore run near USD 335 million, so the bottom-up prehospital figure of $12.6 million to $33.6 million is 3.8% to 10.0% of that segment. That cross-check carries an assumption worth stating: it multiplies a regional revenue share by a global segment share and treats the product as a regional segment size, which holds only if the North American airway-device mix matches the global mix. Subject to that, the two methods agree on order of magnitude.

Reimbursement. Clinician work is already captured under CPT 31500, so no new code is needed for the procedure. The device is the problem: prehospital use is bundled into advanced life support emergency ground transport (HCPCS A0427 and A0433 families) and absorbed by the agency, and in-hospital use is absorbed into the facility payment. This is a capital-and-consumable sale, not a payer negotiation. That lowers the price ceiling, removes coverage-decision risk, and makes demonstrated reduction in complications, rather than procedure revenue, the argument that closes the sale.

6. Research Gap and Commercial Opportunity

The guidance problem has been solved by mechanics rather than computation. The confirmation problem has not been touched, and the 2025 study makes that concrete in its own protocol: every placement was adjudicated by an investigator passing a bronchoscope through the tube to view tracheal rings. No one has combined operator-independent placement with operator-independent confirmation, and until someone does, the category's promise that a minimally trained responder can secure an airway is half delivered.

No onboard sensing of any kind. The device is deliberately non-electronic, which is why it is cheap, sterilisable and shelf-stable, and why it cannot say where the tube went. The opportunity is a sensing and adjudication module that preserves the passive mechanical path while adding a verdict. The candidate modalities, capnometry, airway impedance, acoustic reflectometry and optical mucosal differentiation, are individually mature; none has been integrated into a self-guiding device or reduced to an automated verdict.

No living-airway data. Cadavers lack muscle tone, laryngospasm, secretions and haemorrhage and impose no desaturation clock, so the thesis that morphology substitutes for perception is untested against the physiology that makes intubation hard. Whoever generates the first living-airway dataset owns the evidence base the category will be regulated against.

The failure subgroups are unaddressed. Hayes-Bradley identifies infants, bloody airways, restricted neck movement and distorted anatomy as the drivers of prehospital failure, and none appeared in the eight-cadaver comparison. IVOS Medical has raised $2.1 million of federal money on the bloody-airway case alone, external validation that the subgroups are real, separable and fundable.

No manufacturing data at EMS disposable cost. A single-use everting mechanism with an overmolded introducer must hit an agency consumable price point and survive ambulance temperature cycling and shelf storage. The 2025 paper publishes none of this, and at a sub-$100 million prehospital market unit cost decides whether the segment is addressable at all.

Why the incumbents have not closed it. Verathon, Karl Storz and Ambu sell viewing instruments into a hospital channel through trained buyers, and an operator-independent device cannibalises the training-dependent franchise those channels are built on. Their confirmation business, capnography, is already sold and paid for as monitoring, so integrating adjudication into a disposable airway device shrinks rather than grows their attach. Vine Medical has the opposite constraint: an automated diagnostic claim converts its otherwise straightforward submission into a software-as-a-medical-device question. The rational move for every current player is to leave the confirmation layer alone. The gap is structural, not technical.

7. Comparable Funded Projects

PI	Institution	Funder and program	Project	Amount	FY
Gabriel Punsalan	IVOS Medical, Inc.	NIH NHLBI SBIR	1R43HL164325-01, "IVOS Medical: Intubation, optimized"	$247,334	2022
Gabriel Punsalan	IVOS Medical, Inc.	NIH NHLBI SBIR Phase II	2R44HL164325-02	$824,627	2024
Gabriel Punsalan	IVOS Medical, Inc.	NIH NHLBI	5R44HL164325-03	$926,634	2025
Gabriel Punsalan	IVOS Medical, Inc.	NIH NHLBI	5R44HL164325-04	$144,919	2026
Rick Rutgers	SmartAirway LLC	NIH NHLBI SBIR	1R43HL174223-01A1, articulating stylet for first-pass success	$313,365	2025
Ari Moskowitz	Albert Einstein College of Medicine	NIH NHLBI	1R61HL162980-01, Hospital Airway Resuscitation Trial	$788,728	2022
Robyn Wing	Rhode Island Hospital	NIH NIGMS	P20GM139664, NEAR4PEM pre-intubation checklist implementation	$261,688	2024

All figures were read from the NIH RePORTER v2 API. The DEVICE trial itself was funded by the U.S. Department of Defense, a separate signal: the agency that owns combat casualty care paid to establish the first-pass benchmark.

This validates funder interest and measures the gap. Every award above funds a better tool for a trained operator. A RePORTER search for awards whose title or abstract contains both "intubation" and "robotic" across FY2022 to FY2026 returns exactly one, a robotic enteroscope (1R43DK143858-01A1, Drive Medical, NIDDK, $315,747, FY2025), not an airway device. The absence is instrument-validated with a matched positive control: the identical advanced_text_search surface over the same fiscal years returns 223 awards for "intubation" alone, including both IVOS Medical and SmartAirway, and adding "robotic" collapses it to that single enteroscope. NIH RePORTER records no robotic or autonomous intubation project in five fiscal years, while recording $3,507,295 across the four awards itemised above (the Wing figure is its FY2024 amount only) on the same clinical failure. The claim is scoped to NIH RePORTER and does not cover DoD or other agency records.

8. Opportunity Assessment

TRL 3, composite. A system takes the TRL of its least mature required component, not an average, and the components here are far apart. Operator-independent mechanical placement is TRL 5: a working prototype validated in a relevant environment by the intended end-user population, on the section 3 evidence. The integrated confirmation module is TRL 3: the constituent sensing modalities are mature as standalone monitoring, but no integration into a self-guiding device has been built or published, so the system as a whole is a proof-of-concept. Advancing requires a living airway and a confirmation channel that is not a surgically cut tracheal port.

Technical risks and mitigations.

Living-airway physiology defeats the morphological thesis. Muscle tone, laryngospasm and secretions may make a passive everting path behave differently than in a cadaver. Mitigation: a large-animal study before any human protocol, with a prespecified go/no-go at first-pass success below the 70.8% direct-laryngoscopy arm of DEVICE, the honest floor rather than the 85.1% video arm.

Confirmation sensitivity is inadequate at the clinically relevant operating point. A module 95% sensitive for tracheal placement still misses one oesophageal intubation in twenty, and the Maissan data show the base rate is not small. Mitigation: specify the operating point as sensitivity for detecting oesophageal placement at a fixed false-alarm rate, not overall accuracy, and treat waveform capnography as the reference standard rather than a competitor.

Unit cost exceeds the EMS consumable price point. At a sub-$100 million prehospital market the device must be cheap before it is clever. Mitigation: design for manufacturability from the first prototype, costing the overtube and overmolded introducer against high-volume polymer processing rather than laboratory fabrication.

Competitive displacement risk. If Vine Medical adds confirmation itself, the independent opportunity narrows. The confirmation layer is device-agnostic, applying equally to bougies, supraglottic airways and conventional intubation, and the regulatory incentive runs the other way, since an automated diagnostic claim slows an otherwise straightforward submission.

Regulatory pathway. The two halves separate cleanly, and that separation is the moat.

The mechanical device most plausibly clears through existing airway classes, verified against the FDA classification database: rigid laryngoscopes in CCW, Class I, 21 CFR 868.5540; tracheal tube stylets in BSR, Class I, 21 CFR 868.5790; tracheal tubes in BTR, Class II, 21 CFR 868.5730. Direct precedent exists for a blind intubation guide: the Augustine Intubation Guide cleared under CCW (K882659, 1988; K954446, 1995), and the class remains active with the Prodol Meditec Airtraq (K121378, 2012) and Venner APA Oxy Blade (K191602, 2019). Cook Incorporated's Aintree Intubation Catheter and Arndt Airway Exchange Catheter cleared under BSR (K162729, 2017). A 510(k) is realistic; the framing risk is FDA reading "autonomously guides" as a new intended use without a predicate, which moves it to De Novo. Worth a pre-submission first.

The confirmation module is the harder and more valuable submission. Its nearest product code, not a predicate, is the capnograph (CCK, Class II, 21 CFR 868.1400): a module that outputs a placement verdict rather than a CO2 waveform has different technological characteristics and a different intended use, so substantial equivalence is unlikely to hold. The route is therefore De Novo, and the codes above are cited as the nearest existing classification rather than as a 510(k) path. The locked-versus-adaptive question decides the timeline. A locked algorithm, frozen at clearance and retrained only through a new submission, is the fastest route and the right first choice. Adapting on deployed data is attractive because prehospital airways are heterogeneous and the launch training distribution will be thin, but it requires a Predetermined Change Control Plan under FDA's marketing-submission framework for AI-enabled device software functions, specifying in advance the modifications, the methods used to implement them and the impact assessment. Recommendation: locked at first clearance with a PCCP filed alongside, so the adaptive path is pre-authorised rather than needing a fresh submission later.

That timeline is a moat. A De Novo with a PCCP creates a two to three year barrier a fast-follower cannot compress, in a category where the mechanical device is publicly described and easy to copy. The defensible asset is the cleared diagnostic claim and the living-airway dataset behind it, not the polymer tube. A first-in-human protocol in a population that cannot consent also needs IRB approval plus an exception from informed consent under 21 CFR 50.24, measured in quarters and run in parallel with the animal work.

9. Team Requirements

No single organisation type holds the required capability set, which is much of why the gap has persisted.

Clinical and physiological domain expertise in emergency airway management, to specify the living-airway study, define the failure subgroups that matter and choose the confirmation reference standard. Anatomy and acute physiology, the capability most often missing from a robotics group.

Machine learning system design for a safety-critical binary decision. The confirmation module is a classifier whose relevant metric is sensitivity for detecting misplacement at a fixed false-alarm rate, on a class-imbalanced problem with a thin, heterogeneous training distribution. That demands evaluation methodology and benchmark design as much as model building, plus the regulatory literacy to specify a locked model and a PCCP.

Manufacturing engineering and design for manufacturability. A multi-material single-use assembly, an everting film overtube plus an overmolded introducer, must reach an EMS consumable price point with ambulance-grade shelf stability. At a sub-$100 million prehospital market, manufacturability decides whether the segment exists. It is absent from essentially every academic robotics group and is the most common reason a TRL 5 prototype never becomes a TRL 7 product.

Regulatory strategy spanning two submissions, one airway-device clearance and one software-as-a-medical-device De Novo with a PCCP. Different reviewers, different evidence; running them in parallel is worth roughly a year.

The credible entry is not the guidance mechanism, which is patented, but the confirmation layer and the living-airway evidence base: device-agnostic, unowned, and required before anyone can honestly tell a five-minutes-trained responder that the tube is in the right place.